Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Heplisav-B Approval Has Dynavax Going It Alone On US Launch In Early 2018

13 Nov 2017

• By Sue Sutter

ApproveOnKeyboard_1200x675

Related Content

Merck Returns Heplisav To Dynavax After FDA Rules Vaccine Too Risky For Healthy Adults

19 Dec 2008

Dynavax's Hep B Vaccine Finally Clears US FDA With Clean Label But Larger Safety Study

13 Nov 2017

Related Companies

Dynavax Technologies Corporation

GSK plc

Merck & Co., Inc.

Additional Topics

United States Approvals Launches Vaccines Regulation BioPharmaceutical Infectious Diseases

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.